-
1 Comment
Axonics Modulation Technologies, Inc is currently in a long term uptrend where the price is trading 18.4% above its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.6.
Axonics Modulation Technologies, Inc's total revenue rose by 249.7% to $35M since the same quarter in the previous year.
Its net income has increased by 50.1% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.9% to $-29M since the same quarter in the previous year.
Based on the above factors, Axonics Modulation Technologies, Inc gets an overall score of 4/5.
Industry | Medical Devices |
---|---|
Sector | Healthcare |
ISIN | US05465P1012 |
CurrencyCode | EUR |
Exchange | F |
PE Ratio | None |
---|---|
Target Price | 78.4 |
Dividend Yield | 0.0% |
Market Cap | 3B |
Beta | 0.41 |
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 0I3.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024